A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl
A phase 3 trial of Zanubrutinib, Bendamustine, Rituximab in hodgkin lymphoma and mantle cell lymphoma, run by BeOne Medicines, active and no longer recruiting.
Overview
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation is a phase 3 interventional study registered as NCT04002297 by BeOne Medicines, with 510 participants enrolled, started 2019-08-20 and due to reach its primary completion in 2027-03. Interventions recorded: zanubrutinib, bendamustine, rituximab. Conditions listed: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
- TrialA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
- TrialA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Bendamustine, Mantle cell lymphoma, Rituximab.
- TrialA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Rituximab.
- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares Bendamustine, BeOne Medicines (formerly BeiGene), Rituximab.
- TrialA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Shares Bendamustine, Mantle cell lymphoma, Rituximab.